• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Chiesi Farmaceutici

Resarch Center Chiesi Farmaceutici SpA Parma
Pharma

FDA blesses Chiesi’s Filsuvez for rare skin disease EB

The FDA has given a thumbs up to Chiesi’s Filsuvez to treat the two main types of rare skin disease epidermolysis bullosa.
Kevin Dunleavy Dec 20, 2023 8:20am
Fabry disease

Europe signs off on Protalix, Chiesi's Fabry disease treatment

May 5, 2023 2:40pm
Resarch Center Chiesi Farmaceutici SpA Parma

5 years after European nod, Chiesi wins FDA approval for Lamzede

Feb 17, 2023 10:09am
Accogli

After Amryt buy, Chiesi names Baxter vet Accogli its new CEO

Jan 30, 2023 2:00am
Golden Gate Bridge in San Francisco

JPM23, Day 1: BMS, Regeneron, BioMarin and more

Jan 9, 2023 7:12pm
handshake

Chiesi gets jump-start on JPM buzz with $1.48B Amryt buyout

Jan 9, 2023 9:35am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings